Choose a language and wait for the translated text.
Pembrolizumab, marketed by US giant Merck (known as MSD in India) under the brand name Keytruda is worldβs top selling immunotherapy, which clocked over $31 billion in 2025.
Cipla licenses China's Qilu Pharmaceutical Keytruda biosimilar US rights | PharmaVoice
